文献速递消化系统肿瘤

新辅助帕博利珠单抗治疗局限性微卫星高度不稳定/错配修复缺陷实体瘤

Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors.
PubMed 文献 · J Clin Oncol · 2023-01-09

这项II期开放标签单中心试验纳入35例局限性不可切除或高危可切除的MSI-H/dMMR实体瘤患者,接受帕博利珠单抗200 mg每3周一次共6个月后手术。33例可评估患者最佳总缓解率为82%,17例手术患者病理完全缓解率为65%,无新安全信号。

要点

  • 帕博利珠单抗200 mg每3周一次共6个月新辅助治疗MSI-H/dMMR实体瘤安全,无新安全信号。
  • 33例可评估患者最佳总缓解率为82%,17例手术患者病理完全缓解率为65%。
  • 10例患者选择继续帕博利珠单抗1年后观察而不手术,中位随访23周(范围0-54周)。

核心结论

  • 新辅助帕博利珠单抗在dMMR/MSI-H肿瘤中安全,并获得高比例的病理、影像学和内镜缓解,对器官保留策略有启示。

研究设计与样本

  • II期开放标签单中心试验,纳入局限性不可切除或高危可切除的MSI-H/dMMR实体瘤患者。
  • 治疗方案为帕博利珠单抗200 mg每3周一次共6个月,随后手术切除,可选择继续治疗1年后观察。
  • 共同主要终点为安全性和病理完全缓解,关键次要终点为缓解率和拒绝手术患者1年时的器官保留率。
  • 共纳入35例患者,包括27例结直肠癌和8例非结直肠癌。

主要发现

  • 33例可评估患者最佳总缓解率为82%。
  • 17例(49%)接受手术的患者病理完全缓解率为65%。
  • 10例患者选择接受1年帕博利珠单抗后观察而不手术,中位随访23周(范围0-54周)。
  • 另有8例未接受手术且接受少于1年的帕博利珠单抗。
  • 研究期间及后续随访中,6例患者出现进展事件,其中4例接受挽救性手术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pembrolizumab significantly improves clinical outcomes in advanced/metastatic microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is not well studied in the neoadjuvant space. METHODS: This is a phase II open-label, single-center trial of localized unresectable or high-risk resectable MSI-H/dMMR tumors. Treatment is pembrolizumab 200 mg once every 3 weeks for 6 months followed by surgical resection with an option to continue therapy for 1 year followed by observation. To continue on study, patients are required to have radiographic or clinical benefit. The coprimary end points are safety and pathologic complete response. Key secondary end points are response rate and organ-sparing at one year for patients who declined surgery. Exploratory analyses include interrogation of the tumor immune microenvironment using imaging mass cytometry. RESULTS: A total of 35 patients were enrolled, including 27 patients with colorectal cancer and eight patients with noncolorectal cancer. Among 33 evaluable patients, best overall response rate was 82%. Among 17 (49%) patients who underwent surgery, the pathologic complete response rate was 65%. Ten patients elected to receive one year of pembrolizumab followed by surveillance without surgical resection (median follow-up of 23 weeks [range, 0-54 weeks]). An additional eight did not undergo surgical resection and received less than 1 year of pembrolizumab. During the study course of the trial and subsequent follow-up, progression events were seen in six patients (four of whom underwent salvage surgery). There were no new safety signals. Spatial immune profiling with imaging mass cytometry noted a significantly closer proximity between granulocytic cells and cytotoxic T cells in patients with progressive events compared with those without progression. CONCLUSION: Neoadjuvant pembrolizumab in dMMR/MSI-H cancers is safe and resulted in high rates of pathologic, radiographic, and endoscopic response, which has implications for organ-sparing strategies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ludford K, Ho WJ, Thomas JV, et al. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol. 2023. PMID: 36623241. doi:10.1200/JCO.22.01351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。